Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02328963
Other study ID # CHUBX2012/29
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date May 2, 2014
Est. completion date October 10, 2018

Study information

Verified date November 2018
Source University Hospital, Bordeaux
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after transplantation. It is associated with an increased incidence of acute rejection and lower graft and patient survivals. The goal of this study is to demonstrate that an immunosuppressive regimen associating everolimus and reduced dose of cyclosporine A can prevent acute rejection episodes as efficiently as standard regimen but also efficiently reduce the incidence of CMV infection at 6 months post-transplantation.


Description:

Cytomegalovirus (CMV) infection is the most frequent opportunistic viral infection after kidney transplantation. Therefore most of the patients receive an universal prophylaxis. On the contrary to CMV naïve patients, seropositive recipients (R+) have already mounted a specific immunologic response directed against the virus, which is not completely abrogated by immunosuppressive drugs. Although CMV infection management guidelines offer little guidance on immunosuppressive therapy for preventing CMV infection and disease, recent data plead for reappraising the place of mTOR inhibitors in this situation. The potential anti-CMV action of these molecules could be added to their potential antitumor effect and their equivalent immunosuppressive efficacy in kidney transplant recipients at low immunological risk. By the way, it could represent an alternative of a systematic universal prophylaxis in R+ kidney transplant recipients. However, the proof of this anti-CMV action must be confirmed in vivo in a study, which could have a close monitoring of CMV infection.

We therefore designed a prospective multicentric randomized controlled trial comparing an immunosuppressive regimen based on everolimus and reduced dose of cyclosporine A to a regimen based on mycophenolic acid and standard dose of cyclosporine A, in order to demonstrate the superiority of the first one in the prevention of CMV infection.

Subjects will be randomized to one of the two treatment arms and will be followed for a period of 12 months. Whole blood CMV real time PCR will be performed every week during the first three months, then every two weeks from Month 3 to Month 6, then at Months 8, 10 and 12. Incidence of CMV infection will be compared between the two arms at 6 and 12 months post-transplantation.


Recruitment information / eligibility

Status Completed
Enrollment 186
Est. completion date October 10, 2018
Est. primary completion date October 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age = 18 years.

- End stage kidney disease and a suitable candidate for primary renal transplantation or re-transplantation.

- Patient seropositive for CMV (confirmed within two weeks post-transplant) and having received an allograft from a CMV seropositive or seronegative donor.

- Receiving a kidney transplant from a deceased or living donor with compatible ABO blood type.

- Female subject of childbearing potential must have a negative serum pregnancy test at enrollment and must agree to maintain effective birth control during the study and two months later the discontinuation of the test drug.

- Total ischemia time below 36 hours.

- Capable of understanding the purpose and risks of the study.

- Fully informed and having given written informed consent (signed Informed Consent has been obtained).

- Affiliation to the social security regimen

Exclusion Criteria:

- CMV seronegative patient.

- Historical or current TGI (French equivalence of calculated PRA) > 85 %

- Presence of historical or current anti-HLA donor specific antibodies

- Patient who received anti-CMV therapy within the past 30 days prior to screening.

- Receiving or having previously received an organ transplant other than a kidney.

- Receiving a graft from a non-heart-beating donor.

- Patient known to be positive for Human Immunodeficiency Virus (HIV), Hepatitis B (HBV; HBs Ag positive) or Hepatitis C (HCV; anti-HCV Ab positive).elevated SGPT/ALT and/or SGOT/AST and/or total bilirubin levels = 2 times the upper value of the normal range of the investigational site or receiving a graft from a hepatitis C or B positive donor.

- Significant, uncontrolled concomitant infections and/or severe diarrhea, vomiting, active upper gastro-intestinal tract malabsorption or active peptic ulcer.

- Known allergy or intolerance to everolimus, valganciclovir, ganciclovir, mycophenolic acid, basiliximab, corticosteroids, or cyclosporine A or any of the product excipients.

- Severe hyperlipidemia defined by: total cholestérol = 9,1 mmol/L (= 350 mg/dL) et/ou triglycérides = 8,5 mmol/l (= 750 mg/dL) in spite an adequate medication.

- Patient has adequate hematological post-transplant defined as:

1. Absolute neutrophil count (ANC) > 1000 cells/µL.

2. Platelet count > 50,000 cells/µL.

3. Hemoglobin > 8.0 g/dL.

- Requiring initial therapy with induction immunosuppressive antibody preparations, such as anti-thymocyte globulins or rituximab or IVIG.

- Currently participating in another clinical trial investigating drugs. Observational studies are not considered as an exclusion criteria

- Any form of substance abuse, psychiatric disorder or condition which, in the opinion of the investigator, may complicate communication with the investigator.

- Unlikely to comply with the visits scheduled in the protocol.

Study Design


Intervention

Drug:
Everolimus
Everolimus : 0.75 bid, targeted to 3-8 ng/ml Cyclosporin A : CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12. Corticosteroids : Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
mycophenolic acid
Mycophenolic acid : 1080 mg bid for one month, then 720 mg bid Cyclosporin A : CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12. Corticosteroids : Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study Basiliximab :Day 0: 20 mg ; Day 4: 20 mg

Locations

Country Name City State
France CHU de Bordeaux Bordeaux
France CHU La Cavale Blanche Brest
France CHRU Caen - Hôpital de Caen Caen
France CHU de Limoges - Hôpital Dupuytren Limoges
France Hôpital Edouard Herriot Lyon
France APHP - Hôpital Necker Paris
France APHP - Kremlin Bicetre Paris
France CHRU Strasbourg Strasbourg
France CHU de Toulouse - Hôpital Rangueil Toulouse

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Bordeaux Novartis

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants without CMV infection and without graft loss in CMV seropositive kidney transplant recipients. The primary objective of this study is to compare the survival without CMV infection and without graft loss in CMV seropositive kidney transplant recipients, within the first 6 months post-transplantation when treated with an immunosuppressive regimen including everolimus (Certican®) and reduced dose (RD) of cyclosporine A (Néoral®) versus an immunosuppressive regimen with mycophenolic acid (Myfortic®) and standard dose (SD) of cyclosporine A (Néoral®). 6 months post-transplantation
Secondary Proportion of patients who will develop CMV disease The proportion of patients who will develop CMV disease during the first 6 and 12 months post-transplantation (CMV disease includes both CMV syndrome and CMV tissue-invasive disease). 6 and 12 months post-transplantation
Secondary Proportion of patient with graft loss, death and loss of follow-up 12 months post-transplantation
Secondary Proportion of patient with acute rejection, graft loss, death and loss of follow-u 12 months
Secondary Level to the first CMV DNAemia Throughout the study
Secondary Time to the first CMV disease Throughout the study
Secondary Proportion of patients treated for CMV infection in both groups 6 months
Secondary Half-life of decreasing of DNAemia after initiation of anti-CMV therapy
Secondary Occurrence of treatment failure, defined as the absence of viral eradication. Day 49 (or 8 weeks) after the initiation of anti-CMV therapy
Secondary Occurrence of CMV mutation (UL97 ou UL54) associated with a resistance to an anti-CMV therapy. Throughout the study
Secondary Graft function Graft function defined as glomerular filtration rate (GFR) estimated by simplified MDRD formula and proteinuria/creatininuria ratio. 6 and 12 months post-transplantation
Secondary Proportion of patients with biopsy-proven acute rejection (BPAR) 6 and 12 months post-transplantation
Secondary Degree of interstitial fibrosis/tubular atrophy 12 months on protocol biopsies
Secondary Graft and patient survival 6 and 12 months post-transplantation
Secondary Proportion of BK virus viremia month 1, 3, 6 and 12
Secondary Proportion of patients with adverse events (AE) and/or serious adverse events (SAE) including opportunistic infections and neoplasias. 12 months
Secondary Proportion of patients with haematological disorders The proportion of patients with haematological disorders (neutropenia, anaemia, thrombopenia) 12 months
Secondary Proportion of patients with diarrhea 12 months
Secondary Proportion of dyslipidemia 12 months
Secondary Proportion of patients with occurrence of New Onset Diabetes Mellitus as defined by American Diabetic Association (ADA) criteria. 12 months
Secondary Proportion of patients who will discontinue the immunosuppressive treatment and the reasons why. 12 months
Secondary Proportion of patients with delayed graft function 12 months
Secondary Proportion of lymphocele 12 months
Secondary Time to the first CMV DNAemia Throughout the study
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Terminated NCT01037712 - In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir Phase 4
Completed NCT00370006 - Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IM Phase 1
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT01552369 - CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL") Phase 4
Completed NCT00223925 - Maribavir for Prevention of CMV After Stem Cell Transplants Phase 2
Active, not recruiting NCT05085366 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age Phase 3
Completed NCT01220895 - Alternate Donor Study of Pre-Emptive Cellular Therapy Phase 2
Completed NCT00942305 - Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients Phase 2
Completed NCT00373412 - Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge Phase 1
Completed NCT05105048 - A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 Phase 1
Completed NCT00386412 - TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Phase 2
Completed NCT03382405 - Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults Phase 1
Completed NCT02454699 - Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers Phase 1
Active, not recruiting NCT03910478 - Dried Blood Spot Testing of CMV Detection in HCT Recipients N/A
Completed NCT01354301 - Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Phase 4
Active, not recruiting NCT01473849 - Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients N/A
Completed NCT00880789 - Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus Phase 1
Completed NCT00817908 - Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients N/A
Completed NCT00273143 - A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients. Phase 1